ストックスクリーナーアプリを入手
9.17
4.08%
-0.39
アフターアワーズ：
9.15
-0.02
-0.22%
Contineum Therapeutics Inc (CTNM) 最新ニュース
Contineum Therapeutics (NASDAQ:CTNM) Receives Equal Weight Rating from Morgan Stanley - Defense World
What hedge fund activity signals for Contineum Therapeutics Inc. stockTrade Risk Report & AI Enhanced Execution Alerts - ulpravda.ru
How Contineum Therapeutics Inc. stock compares to market leaders2025 Market WrapUp & AI Driven Stock Movement Reports - ulpravda.ru
Stock Market Recap: How currency fluctuations impact Contineum Therapeutics Inc stock2025 Market Trends & Short-Term High Return Ideas - moha.gov.vn
How interest rate cuts could boost Contineum Therapeutics Inc. stockProduct Launch & Real-Time Market Sentiment Reports - ulpravda.ru
Setup Watch: How interest rate cuts could boost Contineum Therapeutics Inc. stockGold Moves & Weekly Top Performers Watchlists - ulpravda.ru
Can Contineum Therapeutics Inc. stock maintain operating marginsQuarterly Portfolio Report & Fast Moving Stock Trade Plans - ulpravda.ru
Should I hold or sell Contineum Therapeutics Inc. stock in 2025Stop Loss & Smart Allocation Stock Tips - ulpravda.ru
CTNM: Morgan Stanley Downgrades with Lowered Price Target | CTNM Stock News - GuruFocus
Morgan Stanley Downgrades Contineum Therapeutics to Equalweight From Overweight, Adjusts Price Target to $14 From $23 - MarketScreener
Contineum Therapeutics stock downgraded by Morgan Stanley on IPF drug concerns - Investing.com
Contineum Therapeutics stock drops as company prices upsized $90 million offering - MSN
What sentiment indicators say about Contineum Therapeutics Inc. stockSector Performance Review & Explosive Capital Gains - ulpravda.ru
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? - Finviz
Lorrain, Contineum Therapeutics CSO, sells $51k in stock - Investing.com India
Lorrain, Contineum Therapeutics CSO, sells $51k in stock By Investing.com - Investing.com Australia
Contineum Therapeutics announces proposed $75M public offering - MSN
Contineum Therapeutics Submits Phase 2 Trial for PIPE-791 - MSN
Contineum Therapeutics Reports Increased R&D Investment Amid Losses - MSN
Contineum Therapeutics, Inc.(NasdaqGS: CTNM) added to NASDAQ Biotechnology Index - marketscreener.com
Aug Sentiment: Why Contineum Therapeutics Inc. stock is seen as undervaluedInflation Watch & Reliable Intraday Trade Alerts - Улправда
Contineum Therapeutics (NASDAQ:CTNM) Raised to Hold at Wall Street Zen - MarketBeat
Why analysts remain bullish on Contineum Therapeutics Inc. stockMarket Movers & Expert Approved Trade Ideas - Улправда
Why retail investors favor Contineum Therapeutics Inc. stockJuly 2025 Summary & Daily Chart Pattern Signals - Улправда
Why Contineum Therapeutics Inc. stock attracts high net worth investorsWeekly Trend Report & Free Long-Term Investment Growth Plans - Улправда
How risky is Contineum Therapeutics Inc. stock now2025 Trading Volume Trends & Low Risk Entry Point Tips - Улправда
Why Contineum Therapeutics Inc. stock is seen as undervaluedWeekly Profit Recap & Free Technical Pattern Based Buy Signals - Улправда
What risks investors should watch in Contineum Therapeutics Inc. stockOptions Play & Weekly Setup with ROI Potential - Улправда
Published on: 2025-12-19 19:15:06 - Улправда
Why Contineum Therapeutics Inc. stock remains undervaluedEntry Point & Smart Money Movement Alerts - DonanımHaber
Aug Breakouts: Why Contineum Therapeutics Inc. stock is seen as undervalued2025 Earnings Impact & Capital Efficient Trading Techniques - Улправда
Published on: 2025-12-19 11:46:29 - Улправда
Can Contineum Therapeutics Inc. stock deliver strong Q4 earnings2025 Geopolitical Influence & Safe Entry Point Identification - DonanımHaber
Contineum Therapeutics Earnings Notes - Trefis
EBITDA per share of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView — Track All Markets
Great Week for Contineum Therapeutics, Inc. (NASDAQ:CTNM) Institutional Investors After Losing 5.3% Over the Previous Year - 富途牛牛
Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Contineum Therapeutics Inc trading resumes - MSN
Contineum price target lowered to $22 from $25 at RBC Capital - MSN
Contineum Therapeutics Prices Upsized $90 Million Class A Share Offering - marketscreener.com
Contineum prices upsized public offering of common stock at $12.25 per share - Investing.com Nigeria
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Contineum prices upsized public offering of common stock at $12.25 per share By Investing.com - Investing.com South Africa
Contineum Therapeutics prices upsized $90 million public offering at $12.25 per share - marketscreener.com
Contineum Therapeutics (NASDAQ: CTNM) sets price for upsized $90.0M offering - Stock Titan
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering - Business Wire
Contineum Therapeutics launches $75 million public offering of stock By Investing.com - Investing.com Nigeria
0.80%
4.56%
大文字化:
|
ボリューム (24 時間):